Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

@inproceedings{Varenhorst2009GeneticVO,
  title={Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease},
  author={Christoph Varenhorst and Stefan N James and David Erlinge and John T. Brandt and Oscar {\"O}. Braun and Michael Z Man and Agneta Siegbahn and Joseph Chryst Walker and Lars Wallentin and Kenneth J. Winters and Sandra L. Close},
  booktitle={European heart journal},
  year={2009}
}
AIMS The metabolic pathways leading to the formation of prasugrel and clopidogrel active metabolites differ. We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. METHODS AND RESULTS Ninety-eight patients with coronary artery disease (CAD) taking either clopidogrel 600 mg loading dose (LD)/75 mg maintenance dose (MD) or prasugrel 60 mg LD/10 mg MD were genotyped for variation in six CYP genes. Based on CYP… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 109 CITATIONS, ESTIMATED 39% COVERAGE

Genetics of response to antiplatelet therapy.

  • Progress in molecular biology and translational science
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Clopidogrel in Critically Ill Patients

  • Clinical pharmacology and therapeutics
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2009
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response

DS Small, NA Farid, +4 authors KJ. Winters
  • Am J Cardiol
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response

DS Small, NA Farid, +4 authors KJ. Winters
  • Am J Cardiol
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Becquemont L, the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events

T Simon, C Verstuyft, +6 authors N Danchin
  • N Engl J Med
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL